PMID- 37791066
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 2253-5969 (Print)
IS  - 2253-5969 (Electronic)
IS  - 2253-5969 (Linking)
VI  - 10
DP  - 2023
TI  - Transarterial Chemoembolization for Patients with Unresectable Hepatocellular 
      Carcinoma with Child-Pugh B7.
PG  - 1629-1638
LID - 10.2147/JHC.S422300 [doi]
AB  - BACKGROUND AND OBJECTIVES: This study aimed to evaluate the efficacy and safety 
      of transarterial chemoembolization (TACE) in patients with unresectable early or 
      intermediate hepatocellular carcinoma (HCC) and Child-Pugh (CP)-B liver 
      dysfunction. METHODS: This multicenter retrospective study enrolled patients with 
      treatment-naive HCC treated with TACE monotherapy between January 2012 and 
      December 2020 at six Chinese hospitals. The primary outcome was overall survival 
      (OS), and the secondary outcomes included the objective response rate (ORR) 
      according to the modified RECIST and adverse events (AEs). Propensity score 
      matching (PSM) was performed to reduce bias between the CP-B and CP-A groups. 
      RESULTS: A total of 847 patients were included in the study. CP-A patients had 
      significantly longer OS (median, 22.0 vs 19.3 months, P = 0.032) than CP-B (score 
      of 7-9) patients, but a non-significant trend compared with CP-B (score of 7) 
      patients (median, 22.0 vs 20.5 months, P = 0.254). After PSM, the median OS was 
      22.7 months for CP-A patients, while it was 19.3 months for CP-B (score of 7-9) 
      patients (p = 0.026) and 20.5 months for CP-B (score of 7) patients (p = 0.155). 
      CP-A patients achieved a significantly better ORR (53.0% vs 35.8%, P < 0.05) 
      compared to CP-B (score of 7-9) patients, but a non-significant trend was 
      observed in CP-B (score of 7) patients (53.0% vs 51.1%, P > 0.05). The 
      post-embolization syndrome rates in the CP-A and CP-B (score of 7) cohorts were 
      52.1% and 53.3%, respectively. No new safety concerns were observed. CONCLUSION: 
      Patients with HCC with a CP score of 7 receiving TACE showed a similar prognosis 
      and safety profile to CP-A patients.
CI  - (c) 2023 Jiang et al.
FAU - Jiang, Jian-Qiang
AU  - Jiang JQ
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
AD  - Department of Interventional Therapy, Nantong Tumor Hospital, Nantong, People's 
      Republic of China.
FAU - Huang, Jin-Tao
AU  - Huang JT
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Zhong, Bin-Yan
AU  - Zhong BY
AUID- ORCID: 0000-0001-9716-1211
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Wang, Wei-Dong
AU  - Wang WD
AUID- ORCID: 0000-0002-7842-8969
AD  - Department of Interventional Radiology, The Affiliated Wuxi People's Hospital of 
      Nanjing Medical University, Wuxi, People's Republic of China.
FAU - Sun, Jun-Hui
AU  - Sun JH
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, People's Republic of China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Interventional Radiology, Third Affiliated Hospital of Soochow 
      University, Changzhou First Hospital, Changzhou, People's Republic of China.
FAU - Ding, Wen-Bin
AU  - Ding WB
AD  - Department of Interventional Radiology, Nantong First People's Hospital, Nantong, 
      People's Republic of China.
FAU - Ni, Cai-Fang
AU  - Ni CF
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
FAU - Zhu, Xiao-Li
AU  - Zhu XL
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230926
PL  - New Zealand
TA  - J Hepatocell Carcinoma
JT  - Journal of hepatocellular carcinoma
JID - 101674775
PMC - PMC10543745
OTO - NOTNLM
OT  - Child-Pugh grade
OT  - hepatocellular carcinoma
OT  - transarterial chemoembolization
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/10/04 06:44
MHDA- 2023/10/04 06:45
PMCR- 2023/09/26
CRDT- 2023/10/04 04:16
PHST- 2023/06/14 00:00 [received]
PHST- 2023/09/18 00:00 [accepted]
PHST- 2023/10/04 06:45 [medline]
PHST- 2023/10/04 06:44 [pubmed]
PHST- 2023/10/04 04:16 [entrez]
PHST- 2023/09/26 00:00 [pmc-release]
AID - 422300 [pii]
AID - 10.2147/JHC.S422300 [doi]
PST - epublish
SO  - J Hepatocell Carcinoma. 2023 Sep 26;10:1629-1638. doi: 10.2147/JHC.S422300. 
      eCollection 2023.